Transcriptomics

Dataset Information

0

Expression profiling of CLL derived T Cells treated with pevonedistat


ABSTRACT: Novel targeted agents used in therapy of lymphoid malignancies, such as inhibitors of B-cell receptor-associated kinases, are recognized to have complex immune-mediated effects. NEDD8-activating enzyme (NAE) has been identified as a tractable target in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. We and others have shown that pevonedistat (TAK-924), a small molecule inhibitor of NAE, abrogates NF-κB signaling in malignant B cells. However, NF-κB pathway activity is indispensable in immune response, and T-cell function is altered in patients with CLL. Using T cells derived from patients with CLL, we demonstrate that while targeting NAE results in markedly differential expression of NF-κB-regulated genes and downregulation of IL-2 signaling during T-cell activation, T cells evade apoptosis. Meanwhile, NAE inhibition favorably modulates polarization of T cells in vitro, with decreased Treg differentiation and a shift towards TH1 phenotype, accompanied by increased interferon-γ production. These findings were recapitulated in vivo in immunocompetent mouse models. T cells exposed to pevonedistat in washout experiments, informed by its human pharmacokinetic profile, recover NAE activity and maintain their response to T-cell receptor stimulation and cytotoxic potential. Our data shed light on the potential immune implications of targeting neddylation in CLL and lymphoid malignancies.

ORGANISM(S): Homo sapiens

PROVIDER: GSE138560 | GEO | 2019/10/08

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-05-17 | GSE264252 | GEO
2017-06-30 | GSE89637 | GEO
2013-03-08 | GSE36414 | GEO
2024-04-26 | GSE236239 | GEO
2013-03-08 | GSE36415 | GEO
2012-05-01 | E-GEOD-33577 | biostudies-arrayexpress
2016-10-09 | GSE86815 | GEO
2013-10-22 | GSE51286 | GEO
2019-09-14 | GSE134190 | GEO
2018-11-28 | PXD011537 | Pride